Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has earned an average rating of “Moderate Buy” from the twelve ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $10.9091.

Several equities research analysts have commented on the company. Citizens Jmp set a $8.00 target price on Taysha Gene Therapies in a report on Wednesday, November 5th. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Chardan Capital reissued a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, December 29th. Finally, UBS Group set a $11.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, December 4th.

Insider Buying and Selling at Taysha Gene Therapies

In other Taysha Gene Therapies news, CFO Kamran Alam sold 23,849 shares of Taysha Gene Therapies stock in a transaction on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $109,943.89. Following the completion of the sale, the chief financial officer owned 1,443,786 shares of the company’s stock, valued at approximately $6,655,853.46. This trade represents a 1.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sean P. Nolan sold 41,312 shares of the business’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $190,448.32. Following the completion of the transaction, the chief executive officer owned 2,908,257 shares of the company’s stock, valued at $13,407,064.77. This represents a 1.40% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 968,795 shares of company stock worth $4,518,093. Insiders own 3.78% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors have recently made changes to their positions in TSHA. AQR Capital Management LLC grew its stake in shares of Taysha Gene Therapies by 325.6% in the first quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock worth $150,000 after acquiring an additional 82,545 shares during the period. Ethic Inc. purchased a new stake in Taysha Gene Therapies in the second quarter worth approximately $67,000. Tybourne Capital Management HK Ltd. grew its position in Taysha Gene Therapies by 10.7% in the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 4,095,000 shares of the company’s stock worth $9,459,000 after purchasing an additional 395,000 shares during the period. May Hill Capital LLC purchased a new stake in Taysha Gene Therapies during the 2nd quarter valued at $37,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies during the 2nd quarter valued at $186,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

TSHA stock opened at $4.84 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -14.67 and a beta of 1.01. The firm has a 50 day moving average price of $5.00 and a 200-day moving average price of $4.35. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $6.02.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.